ES3048696T3 - Ror1 antibodies - Google Patents

Ror1 antibodies

Info

Publication number
ES3048696T3
ES3048696T3 ES18742575T ES18742575T ES3048696T3 ES 3048696 T3 ES3048696 T3 ES 3048696T3 ES 18742575 T ES18742575 T ES 18742575T ES 18742575 T ES18742575 T ES 18742575T ES 3048696 T3 ES3048696 T3 ES 3048696T3
Authority
ES
Spain
Prior art keywords
seq
amino acid
acid sequence
chain variable
variable domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18742575T
Other languages
English (en)
Spanish (es)
Inventor
Amit Nathwani
Satyen Gohil
Peruta Marco Della
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Application granted granted Critical
Publication of ES3048696T3 publication Critical patent/ES3048696T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES18742575T 2017-07-05 2018-07-05 Ror1 antibodies Active ES3048696T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710835.8A GB201710835D0 (en) 2017-07-05 2017-07-05 ROR1 Antibodies
PCT/GB2018/051914 WO2019008377A1 (en) 2017-07-05 2018-07-05 ANTIBODY ROR1

Publications (1)

Publication Number Publication Date
ES3048696T3 true ES3048696T3 (en) 2025-12-11

Family

ID=59592560

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18742575T Active ES3048696T3 (en) 2017-07-05 2018-07-05 Ror1 antibodies

Country Status (11)

Country Link
US (3) US11466083B2 (https=)
EP (1) EP3649152B1 (https=)
JP (1) JP7242573B2 (https=)
CN (1) CN110891973B (https=)
AU (1) AU2018297630B2 (https=)
CA (1) CA3068196A1 (https=)
DK (1) DK3649152T3 (https=)
ES (1) ES3048696T3 (https=)
GB (1) GB201710835D0 (https=)
MX (1) MX2019015348A (https=)
WO (1) WO2019008377A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
US20230416942A1 (en) * 2020-08-21 2023-12-28 Yale University Nanobody Compositions and Methods of Use of the Same
KR20230053602A (ko) * 2020-08-24 2023-04-21 에피맙 바이오테라퓨틱스 (에이치케이) 리미티드 항-ror1 항체 및 관련된 이중특이적 결합 단백질
TWI818308B (zh) * 2020-09-03 2023-10-11 大陸商和鉑醫藥（上海）有限責任公司 標靶ｒｏｒ１的抗體或其抗原結合片段及製備方法和應用
CA3199586A1 (en) * 2020-11-23 2022-05-27 Samantha J. Busfield Antigen-binding molecules and uses thereof
WO2022182562A1 (en) * 2021-02-23 2022-09-01 BioLegend, Inc. ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN S1 AGENTS AND COMPOSITIONS
AU2022227686A1 (en) 2021-02-25 2023-07-27 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
US20240309116A1 (en) * 2021-07-23 2024-09-19 Zhejiang Shimai Pharmaceutical Co., Ltd. Antibodies against ror1 and uses thereof
CN113956359B (zh) * 2021-10-29 2022-09-16 叶鑫淼 一种抗体及其在抗肿瘤中的应用
CN118302448A (zh) * 2021-12-28 2024-07-05 江苏恒瑞医药股份有限公司 抗ror1抗体和抗ror1抗体药物偶联物及其医药用途
WO2024012434A1 (en) * 2022-07-11 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN115724973B (zh) * 2022-09-26 2023-07-11 普健生物（武汉）科技有限公司 抗人ror1高亲和力兔单克隆抗体及其应用
CN118440200B (zh) * 2023-04-21 2025-05-16 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
CN121666398A (zh) * 2023-08-31 2026-03-13 正大天晴药业集团股份有限公司 靶向受体酪氨酸激酶样孤儿受体1的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
WO2010124188A1 (en) * 2009-04-23 2010-10-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
US20120282177A1 (en) * 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
US9758586B2 (en) 2010-12-01 2017-09-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric rabbit/human ROR1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
DK3252076T3 (da) 2011-01-14 2019-12-02 Univ California Diagnostisk anvendelse af antistoffer mod ror-1-protein
CA2881981A1 (en) 2012-08-20 2014-02-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
KR102048855B1 (ko) * 2014-07-29 2019-11-26 셀렉티스 암 면역요법을 위한 ror1(ntrkr1) 특이적 키메라 항원 수용체
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
RU2753512C2 (ru) 2014-09-08 2021-08-17 Нэшнл Кэнсер Сентер Антитело против злокачественной клетки, противораковое лекарственное средство и способ тестирования злокачественного новообразования
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP3204416A1 (en) 2014-10-09 2017-08-16 EngMab AG Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
EP3253754B1 (en) 2015-02-02 2021-03-31 Kancera AB 2-phenyl-3h-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
EP3842072A1 (en) * 2015-05-18 2021-06-30 Eureka Therapeutics, Inc. Anti-ror1 antibodies
CN108137669B (zh) 2015-05-18 2023-02-17 优瑞科生物技术公司 抗ror1嵌合抗原受体
EA201891066A1 (ru) 2015-10-30 2018-10-31 ЭнБиИ-ТЕРАПЬЮТИКС АГ Антитела к ror1
SG11201806120WA (en) 2016-01-20 2018-08-30 Scripps Research Inst Ror1 antibody compositions and related methods
KR20180100238A (ko) 2016-01-22 2018-09-07 얀센 바이오테크 인코포레이티드 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
CN109563092B (zh) 2016-07-11 2021-09-14 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
WO2018119314A1 (en) 2016-12-22 2018-06-28 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
MX2019013998A (es) 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc Una proteína que se une al receptor nkg2d, al antígeno de cúmulo de diferenciación 16 (cd16) y receptores huérfanos tipo tirosina quinasa 1 o 2 (ror1 o ror2).
MX2019015057A (es) 2017-06-23 2020-08-03 Velosbio Inc Inmunoconjugados de anticuerpos receptor huérfano similar al receptor tirosina cinasa 1 (ror1).
WO2019005636A2 (en) 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
WO2019016381A1 (en) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag MULTISPECIFIC ANTIBODY PRODUCT BINDING TO DIFFERENT ROR1 EPITOPES
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
AU2018360031B2 (en) 2017-11-03 2025-08-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ROR1 immunotherapy
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도

Also Published As

Publication number Publication date
US20230220073A1 (en) 2023-07-13
EP3649152B1 (en) 2025-10-08
AU2018297630B2 (en) 2025-03-06
WO2019008377A1 (en) 2019-01-10
CN110891973A (zh) 2020-03-17
CN110891973B (zh) 2023-06-27
JP7242573B2 (ja) 2023-03-20
MX2019015348A (es) 2020-07-20
DK3649152T3 (da) 2025-11-10
AU2018297630A1 (en) 2020-01-16
US11466083B2 (en) 2022-10-11
CA3068196A1 (en) 2019-01-10
JP2020530272A (ja) 2020-10-22
GB201710835D0 (en) 2017-08-16
US20250066472A1 (en) 2025-02-27
US20200354448A1 (en) 2020-11-12
EP3649152A1 (en) 2020-05-13

Similar Documents

Publication Publication Date Title
ES3048696T3 (en) Ror1 antibodies
ES2906361T3 (es) Anticuerpos biespecíficos para ROR1 y CD3
ES2666131T3 (es) Anticuerpos de mesotelina y métodos para provocar una potente actividad antitumoral
ES2877080T5 (en) Binding molecules specific for cd73 and uses thereof
CN105813654A (zh) Tem8抗体及其用途
JP7711208B2 (ja) Ｄｌｌ３に対する結合分子及びその使用
EP2167542A1 (en) Neutralizing monoclonal antibody against human dll4
TW201623331A (zh) 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
US20230348568A1 (en) Epstein-barr virus monoclonal antibodies and uses thereof
CN111018984B (zh) 抗ck8单克隆抗体及其应用
HK40071055A (en) Bispecific antibodies to ror1 and cd3
KR20250079007A (ko) 2가 cd47 결합 단백질
HK40017928B (en) Bispecific antibodies to ror1 and cd3
HK40017928A (en) Bispecific antibodies to ror1 and cd3
WO2024153146A1 (zh) 抗nmda受体自身免疫性脑炎新型抗体及其用途
WO2025201493A1 (zh) Dll3结合分子及其用途
CN117843781A (zh) Cd138抗体及其应用
WO2022228514A1 (zh) 抗人白血病抑制因子抗体及其用途
CN111040033A (zh) 靶向肿瘤细胞的抗人角蛋白18的单克隆抗体及其应用